Recent Blog Articles

Hand pain from arthritis? This may help

Polio: What parents need to know now

Ketamine for treatment-resistant depression: When and where is it safe?

Have lupus? What to know about birth control

Screening at home for memory loss: Should you try it?

Travel tummy troubles: Here’s how to prevent or soothe them

Easy, delicious summer veggie meals will help stretch your food budget

Tracking viruses: The best clues may be in the sewer

Promising therapy if PSA rises after prostate cancer surgery

Strong legs help power summer activities: Hiking, biking, swimming, and more
Cancer
Promising results for a targeted drug in advanced prostate cancer

- By Charlie Schmidt, Editor, Harvard Medical School Annual Report on Prostate Diseases
It’s well known that defective BRCA genes can increase a woman’s chances of developing breast, ovarian, and other cancers. But these same gene changes can also increase a man’s risk of dying from prostate cancer.
Now, a new study published in The New England Journal of Medicine has shown that men with prostate cancer who test positive for BRCA mutations can benefit from an ovarian cancer drug developed for BRCA-positive women. On the basis of this finding, the U.S. Food and Drug Administration is accelerating its review of the drug, called olaparib, as a possible new prostate cancer treatment.
During the study, 50 men with advanced metastatic prostate cancer took olaparib tablets twice a day. Sixteen of them responded: their prostate-specific antigen levels fell by at least 50%, the number of tumor cells in their blood dropped sharply, and several had their tumors shrink by a third or more in size. Moreover, olaparib improved pain control and quality of life, with responses among some men lasting more than a year. “What was impressive was not just the magnitude of the response, but also its duration,” said Dr. Joaquin Mateo, an oncologist at the London-based Institute of Cancer Research and the study’s lead author.
How olaparib gets its noteworthy results
Olaparib kills BRCA-positive cancer cells by interfering with a DNA repair protein called PARP. And when olaparib-treated cancer cells can’t repair the damage that accumulates naturally in their DNA, they die.
Upon analyzing biopsy samples from the men in the study, Mateo and his co-authors found that responders were limited to men who tested positive for defects in BRCA and a few other related genes. What’s more, the defects in some of the responders weren’t inherited, but rather had developed spontaneously in their cancer cells. Mateo said that’s a critical finding, because PARP inhibitors like olaparib have so far been investigated only in patients with inherited BRCA mutations. “Our trial suggests that many more patients might benefit from the drug, including those who develop DNA repair defects later in life,” he said.
Dr. Marc Garnick, the Gorman Brothers Professor of Medicine at Harvard Medical School and Beth Israel Deaconess Medical Center, and editor in chief of HarvardProstateKnowledge.org, said the findings are promising for the roughly 30% of men with prostate cancer who have DNA repair defects. “Olaparib could provide another, much needed treatment option for many men with advanced prostate cancer,” he said.
About the Author

Charlie Schmidt, Editor, Harvard Medical School Annual Report on Prostate Diseases
Disclaimer:
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
Comments
hello
thanks from your site and Beneficial Articles.
pls connect me to a letter about cancer treatment with
nano gold particles.
with respect
is this testing available now to anyone?
Hi Charles, thanks for getting this blog out. Interesting conclusion of the study.. “Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate.” This is a field that we will be paying more attention to later.
Commenting has been closed for this post.
Free Healthbeat Signup
Get the latest in health news delivered to your inbox!